VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

Hans Hammers, MD, PhD
Published: Thursday, Jan 11, 2018



Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

The CheckMate-214 study demonstrated that frontline treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) reduced the risk of death by 32% compared with sunitinib (Sutent) for patients with metastatic RCC. Across the full study, the confirmed objective response rate was 39% and 32% (P = .0191) in the nivolumab/ipilimumab group and sunitinib group, respectively.

Patients who are still on therapy and not progressing are in the single-digit range, explains Hammers. There is a 21% confirmed response rate from this study.

The phase I CheckMate-016 study investigating PD-1 and CTLA-4 demonstrates a plateau forming in progression-free survival of around 12% to 18%. According to Hammers, the combination of PD-1 and CTLA-4 inhibitors may provide a long-term benefit that is superior to PD-1 monotherapy.
 


Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

The CheckMate-214 study demonstrated that frontline treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) reduced the risk of death by 32% compared with sunitinib (Sutent) for patients with metastatic RCC. Across the full study, the confirmed objective response rate was 39% and 32% (P = .0191) in the nivolumab/ipilimumab group and sunitinib group, respectively.

Patients who are still on therapy and not progressing are in the single-digit range, explains Hammers. There is a 21% confirmed response rate from this study.

The phase I CheckMate-016 study investigating PD-1 and CTLA-4 demonstrates a plateau forming in progression-free survival of around 12% to 18%. According to Hammers, the combination of PD-1 and CTLA-4 inhibitors may provide a long-term benefit that is superior to PD-1 monotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x